Azixa is confirming in phase I the extemely positive expectations.Azixa is the commercial name of mpc 6827 discovered at maxim-epct some years ago ,myriad is ready to launch several phase II this fall.The potential seems to be similar (i think bigger) than oxgn A4P.
(and listen the last mygn conference call for more details)
Myriad Genetics has reported that in a Phase I study of Azixa in cancer that has metastasized to the brain, the drug achieved its maximum tolerated dose in patients. Myriad also noted a measured reduction in tumor size in certain patients, suggesting evidence of activity. Myriad has stated that it is finalizing the therapeutic dose and regimen to bring Azixa forward to Phase II trials shortly.
"We are excited that a compound discovered through the application of our proprietary apoptosis screening technology will soon be entering Phase II trials," remarked Jack Talley, president and chief executive officer. "Our researchers continue to identify promising families of compounds with potentially novel mechanisms to induce apoptosis in cancer cells. As this work proceeds, we are also advancing the lead drug candidates that have already been identified. This includes our anticipated IND filing for EPC2407, a small molecule apoptosis inducer for the treatment of certain types of cancer, later this year."
EpiCept's proprietary apoptosis screening technology can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells through the use of chemical genetics and its proprietary live cell high-throughput caspase-3 screening technology. Azixa represents the first confirmed clinical proof of concept for this new technology, which is the basis for the company's oncology drug discovery efforts.